Skip to main content

Cancer immunotherapy: Recent advances and future perspectives

This international thematic series published in Journal of Hematology & Oncology provides an analysis of the latest developments in the field of cancer immunotherapy. The series is guest edited by Dr. Xiao-Jie Lu.
Articles published in the collection have already gone through the systematic peer review process of the journal.


Fig. 3 from "Target selection for CAR-T therapy" by Dr. Wei et al.

  2. Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, i...

    Authors: Qinghua He, Zhaoyu Liu, Zhihua Liu, Yuxiong Lai, Xinke Zhou and Jinsheng Weng
    Citation: Journal of Hematology & Oncology 2019 12:99
    Content type: Review Published on:

  3. Since the discovery of immune checkpoint proteins, there has been a special interest in developing antibodies that block programmed cell death 1 receptor (PD-1) and programmed cell death receptor ligand 1 (PD-...

    Authors: Akintunde Akinleye and Zoaib Rasool
    Citation: Journal of Hematology & Oncology 2019 12:92
    Content type: Review Published on:

  4. Among all the stromal cells that present in the tumor microenvironment, cancer-associated fibroblasts (CAFs) are one of the most abundant and critical components of the tumor mesenchyme, which not only provide...

    Authors: Tongyan Liu, Chencheng Han, Siwei Wang, Panqi Fang, Zhifei Ma, Lin Xu and Rong Yin
    Citation: Journal of Hematology & Oncology 2019 12:86
    Content type: Review Published on:

  6. Small cell lung cancer (SCLC) is one of the deadliest cancer types in the world. Despite the high response rate to frontline platinum-containing doublets, relapse is inevitable for the majority of patients and...

    Authors: Yaru Tian, Xiaoyang Zhai, Anqin Han, Hui Zhu and Jinming Yu
    Citation: Journal of Hematology & Oncology 2019 12:67
    Content type: Review Published on:

  7. Chimeric antigen receptor-modified T (CAR-T) cells have achieved significant success in the treatment of several hematological malignancies. However, the translation of the existing achievements into the treat...

    Authors: Jianshu Wei, Xiao Han, Jian Bo and Weidong Han
    Citation: Journal of Hematology & Oncology 2019 12:62
    Content type: Review Published on:

  8. Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric an...

    Authors: Hao Wang, Gurbakhash Kaur, Alexander I. Sankin, Fuxiang Chen, Fangxia Guan and Xingxing Zang
    Citation: Journal of Hematology & Oncology 2019 12:59
    Content type: Review Published on:

  9. Immunotherapies have led to substantial changes in cancer treatment and have been a persistently popular topic in cancer research because they tremendously improve the efficacy of treatment and survival of ind...

    Authors: Pengfei Zhao, Li Li, Xiaoyue Jiang and Qin Li
    Citation: Journal of Hematology & Oncology 2019 12:54
    Content type: Review Published on:

  10. Given the success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells in clinical settings, the host immune system plays an important role in the recognition and targeting of tumor cell...

    Authors: Eishiro Mizukoshi and Shuichi Kaneko
    Citation: Journal of Hematology & Oncology 2019 12:52
    Content type: Review Published on: